2 doses of the Pfizer-BioNTech vaccine reduced Omicron hospitalizations by 68% in children 5-11 and by 40% in adolescents 12-18 years old.
The US Food and Drug Administration (FDA) approved the Pfizer-BioNTech COVID-19 vaccine for children 5 years and older in late October 2021. However, as of mid-March 2022, only about 27% of children had received 2 vaccine doses. This is despite the highly infectious Omicron and Delta variants causing severe disease in children at rates unprecedented earlier in the pandemic.
A new study, published yesterday in The New England Journal of Medicine, examined vaccine effectiveness against critical COVID-19 and hospitalization in children and adolescents.
The case-control, test-negative study enrolled patients from July 1, 2021-February 17, 2022. During this time period, the Delta and then Omicron variants caused the majority of COVID-19 infections. Case patients with COVID-19 and controls without COVID-19 were enrolled from 31 hospitals across 23 US states.
The study utilized data from the national Overcoming COVID-19 Network to recruit child and adolescent case patients. Case patients were identified via reviewing hospital admissions logs and electronic medical records. Those hospitalized with COVID-19 or with clinical symptoms indicative of COVID-19 as the primary reason for admittance were included in the case patient group. The control group was matched to the primary study cohort by hospital of admittance, age category (5-11, 12-15, and 16-18 years), and time of hospital admittance.
The investigators estimated vaccine efficacy by the proportion of patients who were fully vaccinated with 2 doses of the Pfizer-BioNTech vaccine at least 14 days before COVID-19 illness. Pfizer-BioNTech is currently the only COVID-19 vaccine authorized for use in children and adolescents under 18 years of age.
The study enrolled 1185 case patients, 88% of whom had not received a COVID-19 vaccine. Of the case patients, 25% (n=291) had severe COVID-19, including 14 who died. Of the 249 adolescents with critical COVID-19, 93% were unvaccinated. Among the 42 children 5-11 years with critical COVID-19, 93% were unvaccinated.
“We hope our findings will help parents make the decision to vaccinate their children and teens against COVID-19,” said Adrienne Randolph, MD, MSc, a co-leader of the study. “The benefits clearly outweigh the risks, as severe infections in childhood can have long-term consequences.”
During the Omicron-predominant period, December 19, 2021-February 17, 2022, vaccine efficacy was 40% against hospitalization, 79% against critical COVID-19, and 20% against noncritical COVID-19 for adolescents 12-18 years of age. Among the children 5-11 years old, vaccine efficacy against hospitalization was 68%.
Because the Pfizer-BioNTech vaccine was granted Emergency Use Authorization (EUA) for children under 12 on October 29, 2021, there was insufficient data to gauge the vaccine efficacy for children during the Delta-predominant period (July 1, 2021-December 18, 2021). In the adolescent cohort, vaccine efficacy against COVID-19-related hospitalization was significantly higher during the Delta period (92% protection) than during Omicron (40% protection).
During both the Delta and Omicron periods, Pfizer-BioNTech vaccination prevented severe and fatal COVID-19. “The reason for a child to get a COVID-19 vaccine is to prevent severe complications of SARS-CoV-2 infection, including hospitalization,” Randolph concluded. “This evidence shows that vaccination reduces this risk substantially in 5- to 11-year-olds. And while vaccination provided adolescents with lower protection against hospitalization with omicron versus delta, it prevented critical illness from both variants.”
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.